Subsequent Events - Additional Information (Details) - Subsequent Event	1 Months Ended
	Jan. 31, 2020 USD ($) payment $ / shares shares
Subsequent Event [Line Items]
Funding adjustment lower or greater threshold	$ 120,000,000
SFJ Pharmaceuticals
Subsequent Event [Line Items]
Payments in co-development agreement	$ 120,000,000.0
Number of quarterly payments | payment	6
Initial Payment | SFJ Pharmaceuticals
Subsequent Event [Line Items]
Payments in co-development agreement	$ 10,000,000
Cost Reimbursements | SFJ Pharmaceuticals
Subsequent Event [Line Items]
Payments in co-development agreement	80,000,000
Achievement of Specified Clinical Development Milestones | SFJ Pharmaceuticals
Subsequent Event [Line Items]
Payments in co-development agreement	30,000,000.0
Upfront Fee at Closing of Transaction | Viamet Pharmaceuticals Holdings, LLC
Subsequent Event [Line Items]
Payments for asset purchase agreement	100,000
Payment Upon Achievement of Certain Development and Intellectual Property Milestones | Viamet Pharmaceuticals Holdings, LLC
Subsequent Event [Line Items]
Payments for asset purchase agreement	5,100,000
Payment Upon Achievement of Commercial Milestones and Royalty Percentages | Viamet Pharmaceuticals Holdings, LLC
Subsequent Event [Line Items]
Payments for asset purchase agreement	142,500,000
FDA Approval Effect to SFJ Pharmaceuticals
Subsequent Event [Line Items]
Payments in co-development agreement	$ 325,000,000
Number of annual payments | payment	7
FDA Approval Effect to SFJ Pharmaceuticals | Initial Payment
Subsequent Event [Line Items]
Payments in co-development agreement	$ 5,000,000
EMA Approval Effect to SFJ Pharmaceuticals
Subsequent Event [Line Items]
Payments in co-development agreement	$ 205,000,000
Number of annual payments | payment	7
EMA Approval Effect to SFJ Pharmaceuticals | Initial Payment
Subsequent Event [Line Items]
Payments in co-development agreement	$ 5,000,000
PMDA and NMPA Approval Effect to SFJ Pharmaceuticals
Subsequent Event [Line Items]
Payments in co-development agreement	$ 59,000,000
Number of annual payments | payment	8
PMDA and NMPA Approval Effect to SFJ Pharmaceuticals | Initial Payment
Subsequent Event [Line Items]
Payments in co-development agreement	$ 1,000,000
SFJ Agreement
Subsequent Event [Line Items]
Term of warrant	10 years
Common stock, warrants (in shares) | shares	2,200,000
Exercise price of warrant (in usd per share) | $ / shares	$ 6.50
Period after effective date of SFJ Agreement | SFJ Agreement
Subsequent Event [Line Items]
Warrants exercisable (in shares) | shares	1,100,000
Period at time of SFJ election | SFJ Agreement
Subsequent Event [Line Items]
Warrants exercisable (in shares) | shares	1,100,000